Topic: estrogen receptors

Alzheimer's disease (AD) is a progressive neurodegenerative condition characterized by extracellular accumulation of amyloid-beta. Estrogen receptors (ERs) are widely recognized as mediators of neuroprotection from various insults. Recent research has highlighted the distinction between nuclear and non-nuclear ER activation mechanisms, positioning non-nuclear ERs as a safer option, devoid of the cardiovascular and cancer risks associated with nuclear ER activation. In this study, we aimed to confirm the neuroprotective potential of PaPE-1, a novel compound that preferentially activates non-nuc

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse reactions in chemotherapy with cytotoxic anticancer agents. We have demonstrated that CIPN caused by paclitaxel involves high mobility group box 1 (HMGB1), a nuclear protein, derived from macrophages (Mφ) in laboratory animals (Neuropharmacology 141, 201, 2018), and that postmenopausal estrogen decline aggravates CIPN in patients undergoing paclitaxel-based chemotherapy (J Pharmacol Sci 146, 49, 2021). In this study, we analyzed estrogen modulation of upstream and downstream mechanisms of HMGB1. Female mice were subje

Global cerebral ischemia (GCI) causes extensive neuronal injury and significant behavioural impairments. Although these sequelae can be mitigated by selective activation of estrogen receptors (ERs), their influence on inflammatory processes mediated by microglial activation are not fully understood. This study characterized the impact of selective ER activation on post-ischemic anxiety-like behaviours and microglial activation. 46 adult female Wistar rats were ovariectomized and, starting the following day, received daily subcutaneous injections of propylpyrazole triol (ERα agonist), diarylpro